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ABSTRACT 
Incidences of arthritic diseases in human have seen recent increases which are thought to have resulted from a complex interplay of several factors, such 
as changes in lifestyle, nutritional insufficiencies, aging and genetic factors. These putative factors possibly lead to different arthritic diseases in humans 
affecting 2-5% of the total population in India. This group of diseases results in serious malfunction and structural abnormalities in the patient body 
leading to permanent and substantial immovability of joints. Conventional medicinal systems usually elicit various side effects in which the defence 
mechanism of the body i.e. the immune system is compromised. In the last few decades many alternative medicinal systems have been developed that 
show promising effects on treating such diseases. Many purified compounds from natural origin, both from plants and animal sources have shown 
promise and many new compounds are continuingly being identified which have no marked side effects. In the light of modern science and technology, 
different natural products and ethnic practices that ensure health, seem to be the best weapon to combat these diseases. Endemic as well as naturalized 
plants from India have been screened by several groups for their anti-arthritic activities. The review summarizes our current knowledge on the 
molecular basis of Rheumatoid Arthritis and discusses the efficacious roles of those natural products, especially of plant origin, in arthritic conditions.  
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INTRODUCTION 
Rheumatoid arthritis (RA) is an autoimmune disease that results in a 
chronic, systemic inflammatory disorder affecting principally the flexible 
(synovial) joints and sometimes adjacent tissues and organs. In severe 
condition of the disease, if kept untreated, it may result in a disabling 
and painful condition, which can lead to substantial loss of function and 
mobility. This debilitating disease is prevalent in all over the world 
including in Indian population. Considering common symptoms, there is 
no strong difference between symptoms of RA and other joint arthritic 
diseases like gout, osteoarthritis or ankylosing spondylytis, so there lays 
a great difficulty in treatment. Early theories on the RA pathogenesis 
focused on autoantibodies and immune complexes [1]. But recent 
reviews focus on autoantibodies as well as T-cell mediated antibody 
responses and T-cell independent cytokine networks [1]. Cytokines are 
now regarded as the very important regulating factors in rheumatoid 
arthritis. Studies from cytokine network interruption by anti-TNF-α 
antibody have shown positive results in collagen-induced arthritic rat 
models [2]. Cytokines are also responsible for the bone destruction near 
the synovial joint where Cytokines like IL-1, IL-17 have been shown to be 
responsible for matrix destruction [3]. Till now, no specific drug is 
available for treating RA. Presently few immunosuppressive drugs like 
glucocorticoids are found to be effective to suppress the disease 
expression and inflammation of the synovial joint, which are 
disadvantageous due to their side effects [4]. 
Ayurveda or ayurvedic medicinal system, a system of traditional 
medicine native to India, is a form of complementary alternative 
medicine that generally depends on different plants and plant-
derived products. However, the science underlying the working 
principle of such herbal products are not revealed in most cases and 
they face a problem of improper clinical trials. Many common Indian 
plants are being studied in different laboratories for their anti-
arthritic and anti-inflammatory properties, which include Green tea 
(Camellia sinensis), Ashoka (Saraca asoca), Tulsi (Ocimum sanctum), 
Devdaru (Cedrus deodara) and many others. Few plants have been 
found to be effective in reducing inflammation and arthritic swelling. 
Several other plants or plant products are also being explored for 
their efficacy. Cytokine gene regulation, cellular signalling 
mechanism and mechanism of bone destruction are being 
extensively studied for that purpose. 
Classification criteria are needed in population studies to establish 
the epidemiology of the disease, to define entry criteria for clinical 
trials, to evaluate whether individuals have the specific disease, and 
to train medical students. The methodology of development of 
classification criteria has gradually been refined over the last 50 
years or so. According to American College of Rheumatology (ACR) 
criteria (1987) a total of 41 rheumatologists from university and 
private practice were asked to provide details of patients aged 16 
years and older whom they considered to have RA and of the next 
consecutive patients who did not have RA or a localized rheumatic 
condition [5]. Based on those details, the following table (table 1) 
presents the classification criteria for arthritic diseases: 
  
Table 1: Classification criteria for arthritic diseases according to the American College of Rheumatology (ACR) criteria, proposed in 1987 [5] 
Types Description 
1. Morning stiffness Morning stiffness in and around the joints, lasting at least for 1 hour before maximal improvement. 
2. Arthritis in three or 
more joint areas 
Soft tissue swelling or fluid (not bony overgrowth) observed by a physician, present simultaneously for at least 6 
weeks. 
3. Arthritis of hand joints Swelling of wrist MCP or PIP for at least 6 weeks. 
4. Symmetrical arthritis Simultaneous involvement of the same joint areas (defined in 2) on both sides of the body (bilateral involvement of 
PIPs, MCPs, or MTPs is acceptable without absolute symmetry for at least 6 weeks. 
5. Rheumatoid nodules Subcutaneous nodules over bony prominences, or extensor surfaces, or in juxta-articular regions, observed by a 
physician. 
6. Rheumatoid factor Detected by a method positive in less than 5% normal controls. 
7. Radiographic changes Typical of RA on postero-anterior hand and wrist radiographs which must include erosions or unequivocal bony 
decalcification localized to or most marked adjacent to the involved joints (osteoarthritis changes alone do not qualify). 
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Rheumatoid arthritis is defined by the presence of four out of the 
seven criteria (table 1) that were developed by the American College 
of Rheumatology (ACR) in 1987 [5]. Symptoms can vary greatly 
depending on the type of arthritis and the individual concerned. In 
the most common forms, joints of the knees, fingers, wrists, ankles, 
hips, and/or elbows become stiff, swollen, tender, and painful. This 
pain can be greater in the morning, or get worse as the day goes on. 
Often fatigue occurs and is sometimes accompanied by a sleep 
disorder. Painless lumps under the skin, called rheumatoid nodules, 
can be felt in RA. In juvenile rheumatoid arthritis, fever, rash, and 
anaemia occur. The symptoms can also be cyclical that appear, 
disappear and reappear with time, where reappearance is often 
termed “flare up” phase. This chronic pain ranges from mild to 
severe and can last for the lifetime.  
As it is an autoimmune disease, genetic factors are predisposed in 
person to initiate the disease. For instance, in some people with RA, 
some specific alleles of HLA genes that affect the immune system are 
found in high frequency. Along with that, lifestyle also plays an 
important role in developing RA. The onset of symptoms can occur 
at a wide range of ages spanning from youth to the elderly although 
most forms become more common with ages. Older people can get 
arthritis because of general wear and tear on joints, as well as a 
direct effect of previous injuries like injuries related to sports. 
Likewise, obesity can also increase stress to joints and can, 
therefore, contribute to arthritis. RA is more prevalent in women, 
while other types of arthritic diseases, like gout, occur more 
frequently in men, therefore there seems to exist a role of hormones 
of the affected individual in eliciting the disease.  
Epidemiology of rheumatoid arthritis 
The rheumatoid arthritic disease affects 0.5–1% of the population in 
the industrialized world and commonly leads to significant disability 
and quality of life is consequently reduced [6]. It is 2 to 3 times more 
frequent in women than in men and can start at any age, with a peak 
incidence between the fourth and sixth decade of life. Its prevalence 
in India ranges from 0.28% in the urban population to 0.55% in the 
rural population as per the survey done [7] but the actual incidence 
range may vary from 2-5% in the country. 
Pathogenesis of rheumatoid arthritis 
RA is regarded as an autoimmune disease. The disease has some strong 
association with several types of auto-antibodies like rheumatoid factor 
(RF), anti-perinuclear factor (APF) and anti-keratin antibodies (AKA), 
anti-collagen antibodies, antibodies to nuclear antigens such as Epstein-
Barr nuclear antigen and RA33, anti-Sa, and anti-p68 antibodies [4]. 
Most of these antibodies react/interact with citrullinated proteins [8]. 
But it is still unknown whether such autoantigens initiate the T-cell 
activation cascade from the very beginning by any signalling pathway to 
form inflammatory changes, or contribute to the disease at a later stage 
to boost and/or perpetuate the disease. 
RA has a polygenic basis and 31 risk loci have been identified. The 
presence of some of those loci in different combinations increases 
the chance of the disease by several folds [9]. In such genetically 
predisposed individuals the innate immune response is possibly 
activated by events such as the triggering of dendritic cells (DCs) 
through TLRs (several of which are known to be expressed on 
synovial cells) by exogenous material or by a combination of foreign 
stimuli together with autologous antigens [1, 10, 11]. Synovial 
dendritic cells activated by TLR ligands can migrate to lymph nodes 
where primed T-cells can be biased towards the TH1 phenotype. The 
synovial membrane is infiltrated by T-cells, which produce IL-2 and 
IFN-γ. So the T-cell response attains a TH1 bias. Further, TH17 cells 
may be an important effect or T-cell subset in RA [12]. These T-cells 
activate monocytes, macrophages and synovial fibroblasts through 
cell–cell contact and activation by different cytokines, such as IFN-γ, 
TNF-α and IL-17 [13, 14]. These immune cells then overproduce 
pro-inflammatory cytokines — mainly TNF-α, IL-1 and IL-6 — which 
seem to constitute the pivotal event leading to chronic inflammation. 
Many other cytokines and chemokines are involved in RA progression, 
including IL-15, IL-18 and angiogenic factors. These molecules, after 
binding to their specific receptors, can regulate various signal 
transduction cascades, such as the MAPK, nuclear factor-κB (NF-κB) or 
Jak/STAT pathways, which ultimately lead to the activation/inhibition 
of transcription factors or subsequent induction of genes responsible 
for mediation of inflammation and tissue degradation. Among these 
products are various cytokines, chemokines and tissue-degrading 
enzymes, such as the matrix metalloproteinases (MMPs), cell-surface 
molecules that enhance cell activation and cell–cell interactions, such 
as co-stimulatory and adhesion molecules like selectins, integrins, that 
are involved in inflammatory pathways creating important 
intercellular interactions pivotal in the inflammatory responses. Apart 
from the inflammatory infiltration in the peri-vascular and sublining 
regions of joints, the lining layer consisting of synoviocytes become 
hyperplastic, and transforms into an aggressive tissue at the cartilage–
bone junction, the ‘pannus’, which contains osteoclasts which is 
responsible for major bone degradation. While degradation of 
cartilage is mainly mediated by a plethora of metalloproteinases 
present in the joint, bone destruction is mediated by the generation 
and activation of osteoclasts, an event that apparently does not occur 
in non-destructive arthritis [15, 16]. The role of B-cells and 
autoantibodies, and/or immune complexes may be important in the 
propagation and enhancement of the inflammatory process. B-cells 
function as effective antigen presenting cells and also produce the 
autoantibodies against RF citrullinated proteins [17]. A schematic 
presentation of the events taking place during RA is shown in the fig. 1. 
A growing body of evidence indicates the possible role of highly 
reactive products of oxygen and nitrogen, termed as free radicals, in 
the pathogenesis of RA as well as other degenerative diseases [18]. 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are 
produced endogenously during aerobic metabolism at the sites of 
chronic inflammation. ROS such as superoxide radical, hydroxyl 
radical and hypochlorous acid contribute significantly to tissue injury 
in RA. In addition, activated leukocytes also produce ROS. Superoxide 
radicals and hydrogen peroxide do not directly damage the majority of 
biomolecules, but they are converted into the highly reactive hydroxyl 
radicals, which react with almost all molecules in living cells. ROS can 
directly or indirectly damage basic articular constituents and lead to 
the clinical expression of the inflammatory arthritis. Synovial cavity 
damage correlates with fluctuating oxygen pressure in the joint, over 
production of ROS, lack of oxygen-processing enzymes and free 
radical-scavenging molecules has been reported in RA. Oxidative 
stress exacerbates inflammation and worsens joint tissue. 
 
 
Fig. 1: Diagrammatic representation of the events of disease 
progression in RA 
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The normal equilibrium between ROS production and anti-oxidant 
system of the cell is disturbed due to oxidative stress, thus resulting 
in the damage to vital cell components such as proteins, DNA and 
membrane lipids. There are several studies demonstrating increased 
levels of malondialdehyde and decrease in the activities of catalase 
in RA patients. Similarly, glutathione reductase activities also get 
disturbed in the synovial fluid of patients. Moreover, the levels of 
thioredoxine, which is a marker of oxidative stress, are significantly 
higher in the synovial fluid of RA patients. Production of nitric oxide 
(NO) is also up regulated in arthritic tissue [18].  
Genetic basis of rheumatoid arthritis 
MHC and Rheumatoid arthritis 
An extensive study of human genetics has been done to identify 
regions of the genome that are reproducibly associated with RA risk. 
Based on genetic information, from a large number of patients, the 
HLA-DRB1 “shared epitope” alleles were first to be recognized in the 
late 1970’s, followed by the discovery of PTPN22 in 2004. In 2007, 
other three new loci have been identified (STAT4, TRAF1-C5, and 
6q23). Several other loci are showing promise, but the involvement of 
these loci with RA is not confirmed yet (CD40, CTLA4, and PADI4) [19].  
The human leukocyte antigen (HLA) region remains one of the most 
powerful disease risk genes in different autoimmune diseases 
including RA. Several allelic variants of HLA-DRB1 genes have been 
associated with RA which supports a role for T-cell receptor-HLA-
antigen to interact in the process. Disease-associated HLA-DRB1 
alleles are polymorphic and certain allelic variants are preferentially 
high in the diseased population. Based on studies on the patients 
with the severe diseased condition a gene dose effect of HLA-DRB1 
alleles has been suggested [20, 21]. Therefore, polymorphisms in 
HLA genes are being explored to find diagnostic tools for a 
rheumatoid syndrome. Besides HLA polymorphisms, other risk 
genes will be helpful in defining genotypic profiles correlating with 
disease phenotypes.  
HLA genes in conjunction with other genetic determinants may lead 
the patient body to a certain pathway of synovial inflammation. 
Patients may or may not develop extra-articular manifestations, 
which are critical in determining morbidity and reducing healthy 
lifespan. HLA genes, complemented by other RA risk genes, are likely 
involved in shaping the T-cell repertoire. On the other hand, 
production of an unusual T-cell population characterized by the 
potential of vascular injury, as seen in extra-articular RA, is also 
accelerated by these genes [22]. 
Cytokines and rheumatoid arthritis 
Cytokines are small polypeptide mediators of the immune and 
inflammatory responses. These molecules are secreted by almost all 
cell types at different titre in different time. Their action is generally 
at a paracrine or autocrine level. Cytokines function in a complex 
process with multiple relationships, making it difficult to predict the 
role of a single cytokine in any disease. The role of cytokines in the 
pathogenesis of RA has been the subject of multiple studies that 
generally agree on the overproduction of pro-inflammatory 
cytokines in the rheumatoid joint. There are several studies to 
monitor the roles of cytokines in different diseases. Most of these 
studies are based on immunohistochemistry or molecular biology 
techniques, which have detected the expression of cytokines (IL-α, 
IL-1b, IL-6, TNF-α, TGF-β) originating predominantly in the 
macrophage-fibroblast cells [23-26]. But it has been difficult to 
detect T-cell derived cytokines (mainly IL-2 and IL-4). However, 
these studies analyzed the synovial samples of patients with a long-
standing disease treated with anti-rheumatic drugs which may alter 
the original profile of cytokine expression [27-29]. 
At present the mRNA expression of a broad spectrum of cytokines 
(IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, TNF-α, TGF-β) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) have been detected 
in the synovial tissues of RA patients. In both early and advanced 
stages of RA, it helps to know the cellular response and expression 
profiles of different cytokine molecules. The studies of the 
expression of HLA molecules during the progression of disease have 
been investigated to define precise cytokine–HLA network [27-29].  
Role of cytokines in bone destruction 
Studies using anti-TNF agents clearly show that they can slow down 
or prevent the progression of bone and cartilage damage in RA [30]. 
This activity probably involves suppression of osteoclasts-like cells 
in the joints [15]. Other cytokines like IL-1 and IL-17 are notable in 
regulating matrix degradation in animal models of arthritis [3]. The 
most exciting development in the pathogenesis of bone destruction 
in RA was the discovery of osteoclast-mediated bone resorption that 
is regulated by the RANK (receptor activator of nuclear factor (NF-
kB) ligand or RANKL. RANKL is expressed by a variety of cell types 
involved in RA, including T-cells and synoviocytes. These cells, in the 
presence of cytokines like TNF-α and M-CSF, contribute to osteoclast 
maturation and activation. The soluble decoy receptor to RANKL, 
Osteoprotegerin (OPG), and RANKL are up regulated in RA, but 
normalize after treatment with TNF inhibitors [31]. The role of 
RANKL in inflammatory joint disease has been confirmed in several 
animal models. For instance, T-cell activation leads to an RANKL-
mediated increase in osteoclasts and bone loss in rat adjuvant 
arthritis [32]. Osteoprotegerin administration to the arthritic 
animals blocks bone destruction but has a very little effect on 
inflammation. RANKL-knockout mice also have diminished bone 
erosion in arthritis models [33]. Cytokine pathways are involved in 
blocking the RANK/RANKL system that in the other hand blocks 
bone decay. 
Mechanisms of cytokine gene expression and new therapeutic 
targets 
As cytokines play a crucial role in any disease as a medium of cell-
cell communication and cellular activation, cytokine regulation has 
been a key factor to regulate diseases like RA. For instance, NF-κB is 
activated in the synovium of patients with RA [34] which then 
regulates several genes, including TNF-α, IL-6, IL-8, inducible nitric 
oxidase synthase (iNOS) and cyclooxygenase-2 (COX-2), that 
contribute to inflammation. After stimulation of innate immunity or 
exposure to pro-inflammatory cytokines, the IκB kinase (IKK) signal 
complex is activated in synoviocytes, leading to phosphorylation of 
IκB [35]. IKKβ is both necessary and sufficient for induction of IL-6, 
IL-8 and intercellular adhesion molecule-1 (ICAM-1) gene 
expression. Targeting NF-κB is an effective therapeutic strategy in 
many animal models of arthritis. For instance, rat adjuvant-induced 
arthritis is suppressed by intra-articular gene therapy with 
dominant negative IKKβ adenoviral construct [36], while decoy 
oligonucleotides block streptococcal cell-wall arthritis [37]. 
The mitogen-activated protein kinases (MAPs) are also key regulators 
of cytokine and metalloproteinase production and could also be a 
target in RA. All three kinase families — extracellular signal-regulated 
kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 are expressed in 
rheumatoid synovial tissue [38]. All are constitutively expressed by 
cultured synoviocytes, and exposure to pro-inflammatory cytokines 
induces rapid phosphorylation. Upstream kinases that activate the 
MAP kinases, such as MKK3, MKK4, MKK6 and MKK7, are also 
activated in RA synovium and can form signalling complexes that 
integrate external environmental stresses to generate an appropriate 
cellular response. The MAP kinases have attracted considerable 
attention as potential therapeutic targets in RA. Pre-clinical studies 
show that p38 inhibitors are effective in murine collagen-induced 
arthritis, rat adjuvant-induced arthritis, and many other RA models 
[39]. A selective JNK inhibitor, SP600125, is mildly anti-inflammatory 
in the rat adjuvant-induced arthritis model but provides striking 
protection against bone and cartilage destruction [40]. Of the JNK 
isoforms, JNK2 is particularly important in arthritis because it is the 
dominant isoform expressed in synoviocytes. In JNK2-knockout mice, 
passive collagen-induced arthritis causes less cartilage damage 
compared to wild-type animals although clinical arthritis is still severe 
[41]. The transcription factor activator protein-1 (AP-1) also regulates 
many genes that participate in RA, including TNF-α and 
metalloproteinases. 
High levels of AP-1 binding activity are detected in nuclear extracts 
of RA synovial tissue compared to osteoarthritis. Its components c-
Jun and c-Fos are highly expressed in RA synovium, especially in the 
nuclei of cells in the intimal lining layer [42]. Pro-inflammatory 
cytokines can activate AP-1 activity in synoviocytes and lead to a 
Bhattacharjee et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 7, 30-39 
33 
massive release of metalloproteinases. AP-1 molecules suppress 
collagen-induced arthritis and inhibit IL-1, IL-6, TNF-α, matrix 
metalloproteinase (MMP)-3 and MMP-9 production in synovial 
tissues [43]. One of the concerns with therapy directed at any of 
these key regulatory pathways is that they also participate in many 
normal cellular functions. The risks of toxicity or impaired host 
defence are significant potential problems because alterations in 
innate immunity or adaptive responses can be possible.  
The advent of TNF inhibitors [44, 45] illustrates the success of 
applied translational research in RA, based on characterization of 
cytokine networks and studies suggesting that TNF-α production 
might serve as an autologous stimulus for other cytokines in RA 
synovium [46]. Although 40% of the patients have dramatic 
responses, the remainder have some evidence of persistent synovitis 
or minimal clinical benefit. IL-1Rα, a natural IL-1 antagonist, has also 
been approved for use in the United States of America. The response 
rates of IL-1Rα are less than that of TNF inhibitors, perhaps because 
IL-1Rα is a competitive antagonist that must be present in large 
excess. Additional cytokine-directed agents, such as anti-IL-6 
receptor antibody, are also in clinical development, preliminary 
response rates being similar to TNF antagonists. Inhibition of IL-18 
and IL-15 represents additional attractive approaches that could 
block TH1 differentiation, production of inflammatory mediators, or 
TNF-α expression. Based on the TH1 bias of T-cells in the synovium, 
treatment with TH2 cytokines (IL-4, IL-10 and IL-13) was tested in 
many animal models of arthritis and has showed considerable 
promise [47]. But so far, administration of IL-10, which serves as a 
prototypic TH2 cytokine, has met with only limited success [48].  
Synthetic drug/plant extract & their efficacy in rheumatoid 
arthritis 
There are two principal approaches to drug therapy for RA [4]: 
• Symptomatic treatment with analgesics such as 
Acetaminophen and opioids, Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs), and intra-articular therapies such as glucocorticoids. 
These drugs only interfere with a small segment of the inflammatory 
cascade (e. g prostaglandin generation by cyclo-oxygenases [COXs]) 
but do not interfere with the underlying immuno-inflammatory 
events or retard joint destruction, and 
• Disease-Modifying Anti-rheumatic Drugs (DMARDs) which 
‘modify’ the disease process in all these respects, and once DMARDs 
are effective, no further symptomatic therapies are needed. 
Examples include methotrexate (MTX), sulfasalazine, leflunomide, 
hydroxychloroquine and few newer therapies such as anti-tumour 
necrosis factor (TNF)-α therapy (etanercept, infliximab and 
adalimumab), anti-CD20 therapy (rituximab) and abatacept. 
All these NSAID and DMARD drugs are limited by low (<70%) 
response rate and induction (>30%) of severe adverse events. Some 
of the newer drugs are able to perform a little better in the remission 
rate and adverse events, but none of them have achieved ideal 
targets. This has been often cited as one of the reasons for increased 
use of complementary and alternative medicine (CAM) by patients 
suffering from RA. About 60% to 90% of patient populations have 
been reported to be using CAM from different countries [49]. 
According to the National Centre for Complementary and Alternative 
Medicine (NCCAM), “Complementary and alternative medicine is a 
group of diverse medical and health care systems, practices, and 
products that are not presently considered to be part of 
conventional medicine” [50]. 
The therapies and practices, included within the scope of 
complementary medicine field, can be broadly categorized into:  
• Treatments in which people can administer themselves (e. g., 
botanical herbs, nutritional supplements, health food, meditation, 
and magnetic therapy), 
• Treatments were administered by providers (e. g., acupuncture, 
chiropractic, massage, reflexology, and osteopathic manipulations), and 
• Treatments people can administer under the periodic supervision 
of a provider (e. g., Tai Chi, yoga, homeopathy, and Ayurveda). 
The world health organization (WHO) estimates that as many as 
80% of the world population depends primarily on animal and plant 
based medicines. Of the 252 essential chemicals that have been 
selected by the WHO, 11.1% come from plants and 8.7% from the 
animals [50]. So there is an increasing need for research in this field. 
Herbal medicine is the root of various traditional medicine systems 
around the world. Various traditional medicine systems around the 
world, including ancient Chinese and Indian medicinal system 
(consisting of two major branches—Unani and Ayurveda), rely 
heavily on herbs for health preservation and healing. Herbal 
medicines have been described in traditional texts and been used as 
anti-microbial, anti-inflammatory and anti-viral medicine for the 
cure of allergies, RA, infections, wound healing and fever. While 
many herbal extracts and formulations have undergone trials at 
different levels and have established their anti-arthritic potential, 
many need more research or remain partially explored. 
At present, the current modalities for treating arthritis have not been 
shown to block, reverse or cure the disease. In these cases, disease 
flares up when the treatment is discontinued because the treatment is 
symptomatic. This has increased the interest of use of CAM therapies 
for the treatment of arthritis. However, much of the current research is 
focused on the identification, isolation and characterization of active 
principle(s) from crude extracts of known medicinal plants/herbs and 
animals/animal products, often overlooking the fact that strong 
synergism of several constituents in the crude drug may prove more 
potent and effective than any single purified compound and this may 
also help to nullify the toxic effects of individual constituents. The lack 
of sufficient clinical investigations too does not permit definitive 
conclusions to be drawn regarding the efficacy of plants and animals 
as CAM modalities in RA. However, several animal model based 
studies have helped in elucidating the potential mechanism of action of 
various CAM modalities. This encourages further studies but demands 
rigorous experimentation. There is a need for screening and 
scientifically evaluating number of known traditional medicinal plants 
and animals for providing newer and safer treatment options with 
minimum side effects. Once the underlying molecular mechanism for 
the observed anti-inflammatory and chondroprotective effects of 
nutraceuticals are elucidated, their health benefits may be fully 
exploited to develop new and better modalities for treating 
degenerative and inflammatory joint diseases. 
Current knowledge on promising plant based medicines 
Camellia sinensis var. assamica (J. W. Hart.) Kitam (Assam tea) 
Camellia sinensis (Family Theaceae) is native to east, south and south-
east Asia, but it is today cultivated across the world in tropical and 
subtropical regions. The pharmacological properties of green tea are 
attributed to its high content of polyphenols/catechins, mainly 
epigallocatechin-3-gallate (EGCG). EGCG inhibits the transcription 
factor nuclear factor kappa-B (NF-κB), IL-1 induced phosphorylation 
of c-Jun-N-terminal kinase (JNK), expression and activities of matrix 
metalloproteinases MMP1 and MMP13 in vitro [51]. The catechin 
constituent of green tea was shown to inhibit the degradation of 
human cartilage proteoglycan and type II collagen. The effects of 
green tea were demonstrated in an animal model of inflammatory 
polyarthritis, wherein the collagen-induced arthritis (CIA) was 
ameliorated by prophylactic administration of green tea polyphenols 
(GTPs) in drinking water. In addition, the total immunoglobulins 
(IgG) and type II collagen levels were found to be lower in the serum 
and arthritic joints of GTP fed mice [18]. Immunostimulatory activity 
[52] and anti-microbial activity [53] of the plant is also promising. 
Curcuma longa L. (Turmeric) 
Turmeric (Family-Zingiberaceae) is a commonly used 
colouring/flavoring agent with a long history of its use in Ayurveda 
for various medicinal conditions. It is native in south-east India and 
needs temperatures between 20-30 °C and a considerable amount of 
annual rainfall to thrive. The major component of turmeric is 
curcumin (diferuloylmethane) which constitutes approximately 
90% of total curcuminoid content. Curcumin is a potent inhibitor of 
the common transcription factor NF-κB [54, 55]. Studies have also 
shown the inhibitory effect of curcumin on the arachidonic acid 
cascade (COX-2 and LOX) by inhibiting the catalytic activities of 
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phospholipases A2, Cγ1, and D. Curcumin also blocks the catabolic 
effects of IL-1 β induced upregulation of MMP-3, and IL-1β-induced 
decrease in type II collagen synthesis, that are known contributors 
in the pathogenesis of RA [56]. 
Zingiber offcinale roscoe (Ginger)  
Ginger (Family-Zingiberaceae) is indigenous to southern China, but 
now it is distributed worldwide and cultivated for different purposes. 
Ginger is a very commonly used dietary constituent worldwide, and is 
known to possess antioxidant, anti-inflammatory, antiseptic, and 
carminative properties. Ginger has a history of its use in Ayurveda for 
treating inflammatory and rheumatic diseases. The anti-inflammatory 
effects of ginger in treating arthritis are believed to be due to 6-
gingerol, which is a pungent phenolic constituent of ginger. The 6-
gingerol inhibits the LPS-induced NO production and effectively 
protects against peroxynitrite-mediated damage. Studies have shown 
that gingerols are excellent inhibitors of LPS-induced PGE2 production 
[57]. In some studies, RA patients experienced the marked reduction 
in pain after consumption of ginger [58, 59]. 
Semecarpus anacardium L. f. (Nut milk extract) 
Semecarpus anacardium (Family-Anacardiaceae) is a deciduous tree 
distributed in the sub-Himalayan tract and in tropical parts of India. 
In traditional medicine, it is highly valued for the treatment of gout, 
rheumatic pains, and cancer (60). The chemical constituents of the 
milk extract of Semecarpus anacardium include flavonoids, phenols, 
and carbohydrates. Studies have shown that Semecarpus anacardium 
or nut milk extract is effective against adjuvant arthritis (61, 62). 
The protective anti-oxidant role of flavonoids, is shown to be due to 
their inhibitory effects on the production of reactive oxygen species 
(ROS) by their free-radical quenching activities, and their potential 
to improve the levels of antioxidants in the body. Flavonoids have 
also been reported to exhibit anti-inflammatory activity by 
inhibition of phospholipase A2, thereby reducing the production of 
pro-inflammatory PGE2, and also by reducing the elevated levels of 
TNF-α and NO. Another protective effect of the plant is by enhancing 
the stability of the lysosomal membrane, thus preventing the 
rupture and release of lysosomal enzymes, which play a major role 
in erosive synovitis in RA (56). Furthermore, this plant has been 
shown to modulate both the humoral and cell-mediated immune 
responses along with its anti-inflammatory effects in adjuvant 
arthritic models. The humoral immunomodulatory response was 
explained by reversion of the elevated levels of IgG and IgA, and the 
cell-mediated immunomodulatory response by inhibition of T-
lymphocyte migration to the inflamed joints. 
Saraca asoca (Roxb.) Willd. (Ashoka) 
The original distribution of Saraca asoca (Family-Fabaceae) was in 
the central areas of the Deccan plateau of India, but now the plant is 
distributed throughout the country. Methanolic extracts of Saraca 
asoca has anti-inflammatory activity in rat arthritic models [63]. 
Treatment with S. asoca has also shown a significant reduction in the 
levels of both plasma and liver lysosomal enzymes. The protein 
bound carbohydrates and urinary collagen contents were also 
decreased at a significant level by the treatment of S. asoca methanol 
extract. Furthermore, treatment of S. asoca reduced the levels of pro-
inflammatory cytokines in adjuvant-induced arthritic rats [64]. 
Ananas comosus (L.) Merr. (Pineapple) 
Ananas comosus (Family-Bromeliaceae), commonly known as 
Pineapple, is native to Central and South America and is grown in 
several tropical and subtropical countries including the Indian 
subcontinent. Chloroform and methanolic extracts of A. comosus leaf 
have shown activity against acute anti-inflammation in carrageenan-
induced paw oedema in Wistar albino rats. The methanolic extract 
was found to be the most potent followed by the chloroform extract 
[65]. Bromelain, a protease extracted from the stem of pineapple 
reduces mild acute knee pain [66]. 
Cannabis sativa L. (Ganja) 
This species belonging to Family Cannabaceae is indigenous to 
Central and South Asia. Cannabis is one of the oldest known 
medicinal plants and produces pharmacologically important 
substances. Among them, most important are the cannabinoids that 
are unique components in the cannabis plant. The 9-
Tetrahydrocannabinol (9-THC) and cannabidiol (CBD) are known to 
be major cannabinoids in the plant. Cannabidiol (CBD), a non-
psychoactive marijuana constituent, was recently shown to act as an 
oral anti-hyperalgesic compound in a rat model of acute 
inflammation [67]. Cannabidiolic acid was shown to be a selective 
cyclo-oxygenase-2 (Cox-2) inhibitory component in cannabis [68]. 
Cannabinoids mediate their physiological and behavioral effects by 
activating specific cannabinoid receptors. With the recent discovery 
of the cannabinoid receptors (CB1 and CB2) and the 
endocannabinoid system, research in this field has expanded 
exponentially. Cannabinoids have been shown to act as potent 
immunosuppressive and anti-inflammatory agents and have been 
shown to mediate the beneficial effects in a wide range of immune-
mediated diseases such as multiple sclerosis, diabetes, septic shock, 
rheumatoid arthritis, and allergic asthma. Cannabinoid receptor 1 
(CB1) is mainly expressed on the cells of the central nervous system 
as well as in the periphery. In contrast, the cannabinoid receptor 2 
(CB2) is predominantly expressed on immune cells [69]. 
Ocimum tenuiflorum L. Syn. Ocimum sanctum L. (Tulsi) 
Ocimum sanctum Linn. (Family-Lamiaceae), a small herb seen 
throughout warmer parts of India, have been recommended by 
Ayurveda for the treatment of bronchitis, bronchial asthma, malaria, 
diarrhoea, dysentery, skin diseases, arthritis, painful eye diseases, 
chronic fever, insect bite etc. The fixed oil (non-volatile part of the 
plant, typically obtained from the seed or nut) of O. sanctum was 
shown to have anti-arthritic activity in Freund's adjuvant-induced 
arthritis, formaldehyde-induced arthritis and also in turpentine oil-
induced joint edema in rats. The fixed oil showed significant anti-
arthritic activities in both models and anti-edema activity against 
turpentine oil-induced joint edema [70]. The oil shows anti-
inflammatory potential due to inhibition of arachidonate metabolism 
and anti-histaminic activity. Eugenol (l-hydroxy-2-methoxy-4-
allylbenzene), the active constituent present in Ocimum sanctum L., 
has been found to be largely responsible for its therapeutic potential. 
Withania somnifera (L.) Dunal (Ashwagandha) 
Withania somnifera (Family-Solanaceae) is a small herb found in 
different parts of India and Nepal. It has promising anti-arthritic 
activity, ascribed to its stabilizing action on lysosomal enzyme 
activities [71]. The aqueous suspension of Withania somnifera root 
powder showed potent inhibitory activity towards the complement 
system, mitogen-induced lymphocyte proliferation and delayed-type 
hypersensitivity reaction. Immunosuppressive effect of W. somnifera 
root powder indicates that it could be a candidate for an 
immunosuppressive drug for inflammatory diseases [72]. Oral 
administration of W. somnifera root powder showed a significant 
increase in the level of lipid peroxides, glycoproteins, and urinary 
constituents with the depletion of antioxidant status and bone 
collagen in arthritic animals [73]. The effect of W. somnifera crude 
ethanol extract was studied on peripheral blood mononuclear cells 
of normal individuals and RA patients and synovial fluid 
mononuclear cells of RA patients in vitro. The study demonstrated 
that crude ethanol extracts of W. somniferra suppressed the 
production of pro-inflammatory molecules in vitro. This activity is 
partly through the inhibition of transcription factors NF-κB and AP-1 
by the constituent with anolide [74]. Withaferin-A, a steroidal 
lactone from W. somnifera shows potent anti-arthritic and anti-
inflammatory activity in arthritic animals [75].  
Moringa oleifera Lam. (Moringa)  
Moringa oleifera (Family-Moringaceae), commonly known as 
moringa, drumstick, and horseradish, is a small, fast-growing tree 
that originates in India. Ethanolic seed extracts of Moringa oliefera is 
shown to have immunosuppressive activity in experimental immune 
inflammation [76]. A rare aurantiamide acetate and 1,3-dibenzyl 
urea has been isolated from the roots of M. oleifera [77]. In a study, 
the anti-arthritic activity of a hydro-alcoholic extract of Moringa 
flowers was investigated in adjuvant-induced arthritis in Wistar rats. 
Body weight, paw edema volume (primary lesion), inflammation at 
non-injected sites, and arthritic index (secondary lesion) in diseased 
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animals was reduced by treatment with the extract as compared to 
untreated control animals. The protective effects of Moringa were 
also noted in serum levels of Rheumatoid Factor (RF) and levels of 
the cytokines, TNF-α and IL-1 in treated diseased animals as 
compared with untreated control animals. Test animals showed 
decreased RF level, TNF-α and IL-2 levels in the serum when treated 
with Moringa. Histopathological sections from animals in the drug 
treatment group showed a protective effect that was evidenced by 
less infiltration of lymphocytes and less angiogenesis as compared 
with sections from arthritic animals [76]. 
Cyanthillium cineveum (L.) H. Rob. Syn. Vernonia cinerea (L.) 
Less (Sahadevi) 
This plant is very common in West and Central Africa but well 
distributed in India as well. It belongs to the Family Asteraceae. 
Latha et al. (1998) [78] tested the anti-inflammatory effect of an 
alcoholic extract from the flower of Cyanthillium cineveum (Syn. 
Vernonia cinerea) (Family-Asteraceae) in adjuvant arthritic rats. 
Changes in paw volume, body and tissue weights and serum and 
tissue enzyme activities of ALT, AST, ACP and cathepsin-D in 
adjuvant rats were reversed by oral administration of 100 mg/kg 
body weight of the flower extract. The extract also reversed the 
major histopathological changes in the hind paws of the arthritic 
rats. Phytochemical studies revealed the presence of alkaloids, 
saponins, steroids and flavonoids [78]. 
Methanolic extract of Cyanthillium cineveum was found to scavenge the 
hydroxyl radical generated by Fenton reaction, superoxides generated 
by photo- reduction of riboflavin and to inhibit lipid peroxidation 
significantly. The drug also scavenged nitric oxide. Intra-peritoneal 
administration of Cyanthillium cineveum was found to inhibit the PMA 
induced superoxide generation in mice peritoneal macrophages. The 
administration of Cyanthillium cineveum to mice significantly 
increased the levels of catalase, superoxide dismutase, glutathione, 
glutathione peroxidase and glutathione-S transferase in blood and 
liver, whereas lipid peroxidation activity was significantly decreased 
[78]. It was also found that Cyanthillium cineveum extract significantly 
inhibited carrageenan-induced inflammation, compared to control 
models. Down regulation of pro-inflammatory cytokine level and gene 
expression data also supported the above results [79]. 
Justicia gendarussa Burm f. (Water willow) 
Justicia gendarussa (Family-Acanthaceae) is a shade-loving, quick-
growing, evergreen plant mostly found in moist areas. It is believed 
to be native to China and is distributed widely across India, Sri 
Lanka, and Malaysia. In Indian and Chinese traditional medicine, the 
leaf of the plant is recommended to treat ailments such as fever, 
hemiplegia, rheumatism, arthritis, headache, ear ache, muscle pain, 
respiratory and digestive disorders. The paw volume and lipid 
peroxide level of hemolysate and liver in arthritic rats were 
significantly reduced to near normal level by administration of 
ethanolic leaf extract of Justicia gendarussa [80]. The decreased level 
of enzymatic antioxidants activities and non-enzymatic antioxidants 
levels was reverted to normal levels when methanolic extract given 
to arthritic rats. The preliminary phytochemical analysis of 
methanolic extract showed the presence of many biologically active 
phytochemicals such as flavonoids, alkaloids, phenolic compounds, 
saponins, glycosides, and tannins and these compounds might be 
responsible for the anti-inflammatory properties. The possible anti-
inflammatory mechanism of the Justicia gendarussa leaf extracts may 
be through its free radical scavenging activity, its stabilizing action 
on lipid peroxide and increased antioxidants levels [81]. 
Another study focused on the anti-inflammatory activity of Justicia 
gendarussa in a carrageenan-induced paw edema assay. Methanolic 
extract of J. gendarussa (JRM) roots significantly inhibited oedema 
formation 5 hours after carrageenan induction. JRM inhibited 
carrageenan-induced change in total cycloxygenase activity; 5-
lipoxygenase and 15-lipoxygenase activities in blood mononuclear 
cells of rats, decreased neutrophil infiltration in paw tissue as shown 
by low myeloperoxidase activity [82]. It also caused an inhibition in" 
with "inhibited cyclooxygenase-2 activity in paw tissue [82]. 
Purification of JRM by liquid–liquid partitioning yielded an ethyl 
acetate fraction of JRM that showed interleukin-6 downregulation 
potential and the ability to inhibit prostaglandin E2 production in 
vivo [82]. 
Premna serratifolia L. (Agnimantha) 
Premna serratifolia (Family-Lamiaceae) is a large shrub widespread 
in the deciduous forests of India. The whole plant possesses 
medicinal properties, useful in the treatment of cardiovascular, skin, 
inflammatory diseases, arthritis, gonorrhoea, rheumatism, anorexia 
and jaundice. The anti-arthritic activity of ethanolic extract of 
Premna serratifolia wood was tested in Freund's adjuvant-induced 
rat arthritis model. The loss in body weight during arthritis 
condition was corrected on treatment with ethanol extract and 
standard drug indomethacin [82]. Biochemical parameters such as 
hemoglobin content, total WBC, RBC, erythrocyte and sedimentation 
rate were also estimated. The ethanolic extract at the dose of 300 
mg/kg body weight inhibited the rat paw edema by 68.32% which is 
comparable to standard drug indomethacin which inhibited 74.87% 
paw edema after 21 days. The observed anti-arthritic activity may be 
due to the presence of phytoconstituents such as irridiod glycosides, 
alkaloids, phenolic compounds and flavonoids [83]. 
Cissampelos pareira L. (Abuta) 
Cissampelos pareira (Family-Menispermaceae) is a common plant 
seen in the subcontinent. In a study, 50% ethanolic extract of C. the 
roots exhibited significant anti-inflammatory activity in acute, 
subacute and chronic models of inflammation in rats [84]. In the 
same study, 50% aqueous ethanolic extract of C. pariera exhibited 
resistance against pain in mice. Further, it also showed resistance 
against adjuvant-induced arthritis in mice [84]. 
Nyctanthes arbor-tristis L. (Harshringar; Shiuli)  
Harshringar or Nyctanthes arbor-tristis (Family-Oleaceae) has been 
used widely as a decoction for the treatment of arthritis and sciatica 
in the Indian ayurvedic system of medicine for centuries. The plant 
has its origin from the Bengal region of India while it is distributed 
all over sub-tropical regions of the country. Arbortristosides, 
nyctanthic acid, and crocetin are the main active principles of the 
plant. Water soluble ethanolic leaf extract has been reported to 
reduce significantly the levels of inflammatory cytokines (IL-1, TNF-
α) in experimental arthritis [85]. 
Swertia chirayita (Roxb.) Buch-Ham. Ex C. B. Clarke (Chirata)  
Swertia chirayita, (Family-Gentianaceae) a herb found abundantly in 
the temperate regions of Himalaya, is commonly used for chronic 
fever, anemia and asthma. The plant inhabits the pastures and slopes 
of the Himalayas and ranges between 2000 to 3,000 metres. 
Chirayita comprises of swerchirin, swertanone and swertianin as 
active components responsible for the anti-inflammatory activity. 
Chirayita is reported to reduce the elevated levels of pro-
inflammatory cytokines IL-1β, TNF-α and IL-6 in experimental 
arthritis as well as in asthmatic conditions [86]. 
Crocus sativus L. (Saffron)  
Saffron (Family-Iridaceae) is native to Greece and south-west Asia 
and it was brought to this country and naturalized later. The plant is 
commonly used as folk medicine for various purposes such as 
aphrodisiac, anti-spasmodic and expectorant. It is a perennial 
flowering plant with very less growing height up to 40 cm. 
Commonly cultivated in Kashmir, the distribution of the plant is seen 
in North America, Greece and Spain as well.  
Saffron stigma possesses anti-inflammatory action due to presence of 
the crocetin and carotenoids. Aqueous and ethanolic extracts of saffron 
petals exhibit radical scavenging as well as anti-inflammatory effects 
in xylene and formalin-induced inflammation [87]. 
Strobilanthus callosus Nees. (Karvi)  
Karvi (Family-Acanthaceae) is another Indian medicinal herb, 
commonly found in the Maharastra state and has been used by the 
local tribals for the treatment of inflammatory disorders. The Lupeol 
and 19α-H Lupeol isolated from the roots of Strobilanthus 
callosus have demonstrated the anti-inflammatory as well as anti-
rheumatic activity in carrageenan-induced oedema [88]. 
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Aloe vera (L.) Burm. f. (Ghritokumari) 
Dermatological aspects of Aloe vera (Family-Xanthorrhoeaceae) are 
very well known in the traditional medicinal systems. In this regard, 
studies on compound isolation are also done revealing the presence 
of potent anti-inflammatory biomolecules in the plant [89]. The 
plant is well distributed in India and neighbouring countries. Anti-
inflammatory activity has been investigated in the Aloe vera crude 
extract in carrageenan-induced arthritic rat models [90]. 
Preliminary studies on anti-arthritic activity have also been done 
[91]. Experiments prove that the plant has some strong protective 
role against inflammation and rheumatism. However, some more 
precise experiments are needed to establish its role in such disease.  
Other important plants with anti-inflammatory activities 
Acacia farnesiana (L.) Willd. [92], Aegle marmelos (L.) Correa (Bel) 
[93], Anacardium occidentale L. (Cashew) [94], Azadirachta indica A. 
Juss. (Neem) [95], Cedrus deodara (Roxb. ex D. Don) G. Don (Deodar) 
[96], Morus indica L. (Mulberry) [97], Emilia sonchifolia (L.) DC. Ex 
DC.[98] are some other promising plants having potential anti-
inflammatory activities. These plants can be further used to 
investigate their role in rheumatoid arthritis. 
 
   
Saraca asoka (Ashok) Cannabis sativa (Ganja) Withania somnifera (Ashwagandha) 
   
Cissampelos pereira (Abuta) Justcia gendarussa (Water willow) Aloe vera (Ghritokumari) 
Fig. 2: Promising medicinal plants of the North-Eastern Himalayan region having anti-arthritic and anti-inflammatory properties. Leaf, 
fruiting bodies and flowers are shown in insets. (Photo courtesy: Garden of Medicinal Plants, University of North Bengal, India) 
 
CONCLUSION 
At present, the current modalities for treating arthritis are 
symptomatic and have not been shown to either block or reverse the 
cartilage degradation and joint destruction. This has resulted in 
heightened interest in the use of CAM therapies for the treatment of 
arthritis. However, much of the current research is focused on the 
identification, isolation and characterization of active principle(s) 
from crude extracts of known medicinal plants/herbs and 
animals/animal products, often overlooking the fact that strong 
synergism of several constituents in the crude drug may prove more 
potent and effective than any single purified compound and this may 
also help to nullify the toxic effects of individual constituents. Also, 
the lack of sufficient clinical investigations does not permit definitive 
conclusions to be drawn regarding the efficacy of plants and animals 
as CAM modalities in RA. However, several animal studies have 
helped elucidate the potential mechanism of action of various CAM 
modalities. This encourages further studies but demands rigorous 
experimentation. There is a need for screening and scientifically 
evaluating number of known traditional medicinal plants and 
animals for providing newer and safer treatment options with 
minimum side effects. Once the underlying molecular mechanism for 
the observed anti-inflammatory and chondro-protective effects of 
nutraceuticals are elucidated, their health benefits may be exploited 
to develop new and better modalities for treating degenerative and 
inflammatory joint diseases. 
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